NDAORALLIQUIDPriority Review
Approved
Aug 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMAGENT (perflubron) is an oral liquid diagnostic imaging agent approved in 1993 for enhancing ultrasound visualization. The mechanism of action and specific clinical indications are not detailed in available data, but perflubron is a perfluorocarbon compound historically used as a contrast medium. This product represents an aging diagnostic portfolio with limited current commercial activity.
LOE Approaching
Minimal commercial activity with only 3 linked jobs; team likely small and focused on managed care or legacy product maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Only 3 linked jobs exist for IMAGENT, predominantly in commercial account management rather than clinical or scientific roles. This product offers minimal career growth or advancement potential given its legacy status and approaching loss of exclusivity.
Commercial Lines Account ManagerCommercial Lines
Worked on IMAGENT at Alliance Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.